Literature DB >> 18618373

Human metapneumovirus pneumonia in children: results of an Italian study and mini-review.

Massimiliano Don1, Matti Korppi, Francesca Valent, Raija Vainionpaa, Mario Canciani.   

Abstract

Human metapneumovirus (hMPV) is a newly identified paramyxovirus causing lower respiratory tract infections (LRTI). Current knowledge on hMPV is mainly based on retrospective studies performed in stored respiratory and serum samples. We found 15 previous prospective clinical studies on LRTI (11 clinical and 4 epidemiological studies) that have been reviewed. Our aims were to analyse the role of hMPV in community acquired pneumonia (CAP) and the seroconversion rate to hMPV in a prospective study in North Italian children. During a 15-month study period, 124 children were admitted due to presumptive CAP and, in 116 of them, CAP was radiologically confirmed. The aetiology of CAP was assessed by serology to 15 microorganisms, including enzyme immunoassay to hMPV. hMPV infection was found in 5 children (4.9%), being single in 2 and mixed in 3 cases. The seroconversion rate to hMPV increased with age, reaching nearly 100% seropositivity rate at school age. In conclusion, hMPV caused 0% to 17.5% of LRTI cases in children in the mini-review. The figure was about 5% in the present and in the only earlier paediatric CAP study. Thus, hMPV is a real but rare cause of paediatric CAP, although seroconversion to hMPV in most children takes place in early childhood.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618373     DOI: 10.1080/00365540802227110

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

1.  Human metapneumovirus fusion protein triggering: Increasing complexities by analysis of new HMPV fusion proteins.

Authors:  J Tyler Kinder; Edita M Klimyte; Andres Chang; John V Williams; Rebecca Ellis Dutch
Journal:  Virology       Date:  2019-03-07       Impact factor: 3.616

2.  Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks Infection in Human Lung Cells and Airway Tissues.

Authors:  Edita M Klimyte; Stacy E Smith; Pasqua Oreste; David Lembo; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

3.  Biomarkers for community-acquired pneumonia in the emergency department.

Authors:  Todd A Florin; Lilliam Ambroggio
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 4.  Human Metapneumovirus: lessons learned over the first decade.

Authors:  Verena Schildgen; Bernadette van den Hoogen; Ron Fouchier; Ralph A Tripp; Rene Alvarez; Catherine Manoha; John Williams; Oliver Schildgen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

5.  Prediction of delayed recovery from pediatric community-acquired pneumonia.

Authors:  Massimiliano Don; Francesca Valent; Mario Canciani; Matti Korppi
Journal:  Ital J Pediatr       Date:  2010-07-29       Impact factor: 2.638

6.  Sole infection by human metapneumovirus among children with radiographically diagnosed community-acquired pneumonia in a tropical region.

Authors:  Cristiana M Nascimento-Carvalho; Maria-Regina A Cardoso; Olli Ruuskanen; Maija Lappalainen
Journal:  Influenza Other Respir Viruses       Date:  2011-02-09       Impact factor: 4.380

7.  The clinical impact of PCR-based point-of-care diagnostic in respiratory tract infections in children.

Authors:  Anna Theresa Reischl; Daniel Schreiner; Krystyna Poplawska; André Kidszun; Fred Zepp; Britta Gröndahl; Stephan Gehring
Journal:  J Clin Lab Anal       Date:  2020-02-07       Impact factor: 2.352

8.  The impact of viral infections in children with community-acquired pneumonia.

Authors:  Chiara Mameli; Gian Vincenzo Zuccotti
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 9.  Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity.

Authors:  Nour Akhras; Jason B Weinberg; Duane Newton
Journal:  Infect Dis Rep       Date:  2010-08-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.